Vaccines have proven effective in protecting populations against COVID-19,including the recombinant COVID-19 vaccine(Sf9 cells),the first approved recombinant protein vaccine in China.In this positive-controlled trial...Vaccines have proven effective in protecting populations against COVID-19,including the recombinant COVID-19 vaccine(Sf9 cells),the first approved recombinant protein vaccine in China.In this positive-controlled trial with 85 adult participants(Sf9 cells group:n=44;CoronaVac group:n=41),we evaluated the safety,immunogenicity,and protective effectiveness of a heterologous boost with the Sf9 cells vaccine in adults who had been vaccinated with the inactivated vaccine,and found a post-booster adverse events rate of 20.45%in the Sf9 cells group and 31.71%in the CoronaVac group(p=0.279),within 28 days after booster injection.Neither group reported any severe adverse events.Following the Sf9 cells vaccine booster,the geometric mean titer(GMT)of binding antibodies to the receptor-binding domain of prototype SARS-CoV-2 on day 28 post-booster was significantly higher than that induced by the CoronaVac vaccine booster(100,683.37 vs.9,451.69,p<0.001).In the Sf9 cells group,GMTs of neutralizing antibodies against pseudo SARS-CoV-2 viruses(prototype and diverse variants of concern[VOCs])increased by 22.23–75.93 folds from baseline to day 28 post-booster,while the CoronaVac group showed increases of only 3.29–10.70 folds.Similarly,neutralizing antibodies against live SARS-CoV-2 viruses(prototype and diverse VOCs)increased by 68.18–192.67 folds on day 14 post-booster compared with the baseline level,significantly greater than the CoronaVac group(19.67–37.67 folds).A more robust Th1 cellular response was observed with the Sf9 cells booster on day 14 post-booster(mean IFN-γ+spot-forming cells per 2×105 peripheral blood mononuclear cells:26.66 vs.13.59).Protective effectiveness against symptomatic COVID-19 was approximately twice as high in the Sf9 cells group compared to the CoronaVac group(68.18%vs.36.59%,p=0.004).Our study findings support the high protective effectiveness of heterologous boosting with the recombinant COVID-19 vaccine(Sf9 cells)against symptomatic COVID-19 of diverse SARS-CoV-2 variants of concern,while causing no apparent safety concerns.展开更多
The emergence of adapted variants of the SARS-CoV-2 virus has led to a surge in breakthrough infections worldwide.A recent analysis of immune responses in people who received inactivated vaccines has revealed that ind...The emergence of adapted variants of the SARS-CoV-2 virus has led to a surge in breakthrough infections worldwide.A recent analysis of immune responses in people who received inactivated vaccines has revealed that individuals with no prior infection have limited resistance to Omicron and its sub-lineages,while those with previous infections exhibit a significant amount of neutralizing antibodies and memory B cells.However,specific T-cell responses remain largely unaffected by the mutations,indicating that T-cell-mediated cellular immunity can still provide protection.Moreover,the administration of a third dose of vaccine has resulted in a marked increase in the spectrum and duration of neutralizing antibodies and memory B cells in vivo,which has enhanced resistance to emerging variants such as BA.2.75 and BA.2.12.1.These results highlight the need to consider booster immunization for previously infected individuals and the development of novel vaccination strategies.The rapid spread of adapted variants of the SARS-CoV-2 virus presents a significant challenge to global health.The findings from this study underscore the importance of tailoring vaccination strategies based on individual immune backgrounds and the potential need for booster shots to combat emerging variants.Continued research and development are crucial to discovering new immunization strategies that will effectively protect public health against the evolving virus.展开更多
基金supported by National Natural Science Foundation of China(grants 92159302)the Science and Technology Foundation of Sichuan Province,China(2020YFS0572,2022NSFSC0842)+4 种基金the Key Research and Development Program of Sichuan-Chongqing of the Chongqing Science and Technology Commission(CSTB2022TIAD-CUX0001)the Fundamental Research Funds for the Central Universities(SCU2022D025)the 1.3.5 Project for Disciplines of Excellence at West China Hospital,Sichuan University(ZYGD22009)We are grateful to WestVac BioPharma Co.,Ltd.(Chengdu,China)for supplying the recombinant COVID-19 vaccine(Sf9 cells)in this studyWe are also grateful to Fangcao Community Health Service Center of Chengdu High-tech Zone of Sichuan Province for assisting the on-site implementation.
文摘Vaccines have proven effective in protecting populations against COVID-19,including the recombinant COVID-19 vaccine(Sf9 cells),the first approved recombinant protein vaccine in China.In this positive-controlled trial with 85 adult participants(Sf9 cells group:n=44;CoronaVac group:n=41),we evaluated the safety,immunogenicity,and protective effectiveness of a heterologous boost with the Sf9 cells vaccine in adults who had been vaccinated with the inactivated vaccine,and found a post-booster adverse events rate of 20.45%in the Sf9 cells group and 31.71%in the CoronaVac group(p=0.279),within 28 days after booster injection.Neither group reported any severe adverse events.Following the Sf9 cells vaccine booster,the geometric mean titer(GMT)of binding antibodies to the receptor-binding domain of prototype SARS-CoV-2 on day 28 post-booster was significantly higher than that induced by the CoronaVac vaccine booster(100,683.37 vs.9,451.69,p<0.001).In the Sf9 cells group,GMTs of neutralizing antibodies against pseudo SARS-CoV-2 viruses(prototype and diverse variants of concern[VOCs])increased by 22.23–75.93 folds from baseline to day 28 post-booster,while the CoronaVac group showed increases of only 3.29–10.70 folds.Similarly,neutralizing antibodies against live SARS-CoV-2 viruses(prototype and diverse VOCs)increased by 68.18–192.67 folds on day 14 post-booster compared with the baseline level,significantly greater than the CoronaVac group(19.67–37.67 folds).A more robust Th1 cellular response was observed with the Sf9 cells booster on day 14 post-booster(mean IFN-γ+spot-forming cells per 2×105 peripheral blood mononuclear cells:26.66 vs.13.59).Protective effectiveness against symptomatic COVID-19 was approximately twice as high in the Sf9 cells group compared to the CoronaVac group(68.18%vs.36.59%,p=0.004).Our study findings support the high protective effectiveness of heterologous boosting with the recombinant COVID-19 vaccine(Sf9 cells)against symptomatic COVID-19 of diverse SARS-CoV-2 variants of concern,while causing no apparent safety concerns.
基金supported by National Natural Science Foundation of China(92159302 to W.M.L.)the Fundamental Research Funds for the Central Universities(SCU2022D025 to W.M.L.)+2 种基金Science and Technology Foundation of Sichuan Province,China(2022NSFSC0842 to W.X.L.,2020YFS0572 to L.Y.L.)Ministry of Science and Technology of China(EKPG21-09 and CPL-1233)supported by Ten Thousand Talent Program and the NSFS Innovative Research Group(No.81921005).
文摘The emergence of adapted variants of the SARS-CoV-2 virus has led to a surge in breakthrough infections worldwide.A recent analysis of immune responses in people who received inactivated vaccines has revealed that individuals with no prior infection have limited resistance to Omicron and its sub-lineages,while those with previous infections exhibit a significant amount of neutralizing antibodies and memory B cells.However,specific T-cell responses remain largely unaffected by the mutations,indicating that T-cell-mediated cellular immunity can still provide protection.Moreover,the administration of a third dose of vaccine has resulted in a marked increase in the spectrum and duration of neutralizing antibodies and memory B cells in vivo,which has enhanced resistance to emerging variants such as BA.2.75 and BA.2.12.1.These results highlight the need to consider booster immunization for previously infected individuals and the development of novel vaccination strategies.The rapid spread of adapted variants of the SARS-CoV-2 virus presents a significant challenge to global health.The findings from this study underscore the importance of tailoring vaccination strategies based on individual immune backgrounds and the potential need for booster shots to combat emerging variants.Continued research and development are crucial to discovering new immunization strategies that will effectively protect public health against the evolving virus.